ScholarLens Back to search
2009•AIDSRequires access

Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals

Jasper van der Lugt, Meena Gorowara, Anchalee Avihingsanon, David M. Burger, Jintanat Ananworanich, Kancharat Sringam, Stephen J. Kerr, Ferdinand Wit, Joep M. A. Lange, Kiat Ruxrungtham

Open publisher page 9 citations

Abstract

Currently, the optimal boosting dose for saquinavir is unknown. Therefore, we evaluated the pharmacokinetics profiles in a cross over setting comparing saquinavir/ritonavir 1500/50 mg (plus NRTI backbone) to saquinavir/ritonavir 1500/100 mg in the same HIV-infected, Thai individuals. The 50% reduction of ritonavir boosting did not result in a change in the pharmacokinetics of saquinavir, whereas the ritonavir exposure was significantly lower when a dose of 50 mg was administered.

About this research paper

What this paper is about

Currently, the optimal boosting dose for saquinavir is unknown. Therefore, we evaluated the pharmacokinetics profiles in a cross over setting comparing saquinavir/ritonavir 1500/50 mg (plus NRTI backbone) to saquinavir/ritonavir 1500/100 mg in the same HIV-infected, Thai individuals. The 50% reduction of ritonavir boosting did not result in a change in the pharmacokinetics of saquinavir, whereas the ritonavir exposure was significantly lower when a dose of 50 mg was administered.

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Currently, the optimal boosting dose for saquinavir is unknown. Therefore, we evaluated the pharmacokinetics profiles in a cross over setting comparing saquinavir/ritonavir 1500/50 mg (plus NRTI backbone) to saquinavir/ritonavir 1500/100 mg in the same HIV-infected, Thai individuals. The 50% reduction of ritonavir boosting did not result in a change in the pharmacokinetics of saquinavir, whereas the ritonavir exposure was significantly lower when a dose of 50 mg was administered.

Key concepts: Saquinavir, Ritonavir, Pharmacokinetics, Boosting (machine learning), Pharmacology, Medicine, Human immunodeficiency virus (HIV), Virology

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals — Research Paper | ScholarLens